Abstract
Some experts have proposed combating rising drug prices by promoting brand-brand competition, a situation that is supposed to arise when multiple US Food and Drug Administration (FDA)-approved brand-name products in the same class are indicated for the same condition. However, numerous reports exist of price increases following the introduction of brand-name competition, suggesting that it may not be effective. We performed a systematic literature review of the peer-reviewed health policy and economics literature to better understand the interplay between new drug entry and intraclass drug prices. We searched PubMed and EconLit for original studies on brand-brand competition in the US market published in English between January 1990 and April 2019. We performed a qualitative synthesis of each study's data, recording its primary objective, methodology, and results. We found 10 empirical investigations, with 1 study each on antihypertensives, anti-infectives, central nervous system stimulants for attention deficit/hyperactivity disorder, disease-modifying therapies for multiple sclerosis, histamine-2 (H2) blockers, and tumor necrosis factor (TNF) inhibitors; 2 studies on cancer medications; and 2 studies on all marketed or new dr...Continue Reading
References
Apr 12, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Joel Lexchin
Sep 28, 2007·PLoS Medicine·G Michael AllanNatasha Wiebe
Mar 6, 2008·JAMA : the Journal of the American Medical Association·Rebecca L WaberDan Ariely
Oct 27, 2010·PLoS Medicine·Geoffrey K SpurlingAgnes I Vitry
Feb 18, 2011·JAMA : the Journal of the American Medical Association·Joshua J Gagne, Niteesh K Choudhry
Dec 15, 2012·Journal of Health Economics·Maria-Angeles de FrutosGeorges Siotis
Jan 30, 2015·Neurology·Alberto J EspayJerzy P Szaflarski
Jun 1, 2013·The Journal of Industrial Economics·Farasat A S Bokhari, Gary M Fournier
Apr 8, 2015·Health Affairs·Scott D Ramsey
Apr 26, 2015·Neurology·Daniel M HartungRuth H Whitham
May 7, 2015·The New England Journal of Medicine·Ameet SarpatwariAaron S Kesselheim
Aug 24, 2016·JAMA : the Journal of the American Medical Association·Aaron S KesselheimAmeet Sarpatwari
Jan 25, 2017·JAMA : the Journal of the American Medical Association·Jerry Avorn
Jan 1, 2015·The Journal of Economic Perspectives : a Journal of the American Economic Association·David H HowardRena M Conti
May 31, 2017·JAMA Internal Medicine·Stacie B DusetzinaPeter B Bach
Oct 11, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Noa GordonDaniel A Goldstein
Dec 28, 2017·The New England Journal of Medicine·Chintan V DaveAaron S Kesselheim
Feb 15, 2018·Health Affairs·Gigi A CucklerJames C Hardesty
May 26, 2018·JAMA : the Journal of the American Medical Association·Ameet SarpatwariAaron S Kesselheim
Nov 12, 2018·Clinical Pharmacology and Therapeutics·Ameet SarpatwariAaron S Kesselheim
Jan 9, 2019·JAMA : the Journal of the American Medical Association·Lisa M Schwartz, Steven Woloshin
Feb 19, 2019·JAMA Internal Medicine·Alvaro San-Juan-RodriguezInmaculada Hernandez
Jul 2, 2019·Health Affairs·Ariel D SternAmeet Sarpatwari
Citations
Sep 12, 2020·JAMA Network Open·Sean Dickson
Sep 16, 2020·Health Economics Review·Kyung-Bok Son
Jun 1, 2020·Bone Marrow Transplantation·Salvatore FiorenzaJoshua A Roth
Jan 23, 2021·JAMA Network Open·Patrick LiuJoseph S Ross
Mar 23, 2021·The Milbank Quarterly·VÉronique C RaimondAaron S Kesselheim
May 1, 2021·Vaccines·William Douglas Evans, Jeff French
May 4, 2021·Health Affairs·Ameet SarpatwariAaron S Kesselheim
May 15, 2021·Health Economics·Frank R Lichtenberg
Jul 17, 2021·BMJ Open·Jules M Janssen DaalenBart J F van den Bemt